Xiidra for Dry Eyes: What Canadians Need to Know

Xiidra (lifitegrast) is a prescription eye drop medication specifically designed to treat dry eye disease by reducing inflammation on the eye's surface. For Canadians seeking relief from chronic dry eye symptoms, understanding how this medication works, its availability, and insurance coverage options can help make informed treatment decisions.

What is Xiidra and How Does It Work?

Xiidra (lifitegrast ophthalmic solution 5%) is the first medication in a class of drugs called lymphocyte function-associated antigen-1 (LFA-1) antagonists approved for treating the signs and symptoms of dry eye disease. Unlike temporary lubricating eye drops, Xiidra targets the underlying inflammation that contributes to chronic dry eye syndrome.

The active ingredient, lifitegrast, works by inhibiting the interaction between two proteins (LFA-1 and ICAM-1) that play a role in the inflammatory process. By blocking this interaction, Xiidra helps reduce inflammation on the ocular surface, addressing one of the root causes of dry eye disease rather than just temporarily relieving symptoms. The medication is typically prescribed as one drop in each eye, twice daily, approximately 12 hours apart.

Xiidra Availability in Canada

Xiidra received approval from Health Canada in 2018, making it available by prescription to Canadian patients suffering from dry eye disease. The medication is dispensed in single-use containers, with each package containing enough doses for a 30-day supply when used as directed.

To obtain Xiidra in Canada, patients must first consult with an eye care professional such as an optometrist or ophthalmologist who can diagnose dry eye disease and determine if Xiidra is an appropriate treatment option. After receiving a prescription, the medication can be filled at most Canadian pharmacies. However, availability may vary by location, so it's advisable to call ahead to confirm stock before visiting a pharmacy.

Xiidra vs. Other Dry Eye Treatments

When comparing dry eye treatments available in Canada, several factors distinguish Xiidra from alternatives:

Xiidra vs. Restasis: While both are prescription medications for dry eye, they work differently. Restasis (cyclosporine) increases tear production by reducing inflammation, while Xiidra from Novartis blocks the inflammatory pathway directly. Some patients who haven't responded well to Restasis have found relief with Xiidra.

Xiidra vs. Over-the-Counter Options: Unlike artificial tears such as Systane or Refresh Tears, which provide temporary moisture, Xiidra addresses the underlying inflammatory cause of dry eye disease. Over-the-counter options may need to be applied multiple times throughout the day, while Xiidra is used just twice daily.

Comparison Table:

Treatment	Type	Mechanism	Prescription Required	Application Frequency
Xiidra	Prescription	LFA-1 antagonist	Yes	Twice daily
Restasis	Prescription	Immunosuppressant	Yes	Twice daily
Systane	OTC	Lubricant	No	As needed
Refresh Tears	OTC	Lubricant	No	As needed

Benefits and Potential Side Effects

Clinical studies have shown that Xiidra can provide significant improvement in both the signs and symptoms of dry eye disease, often with noticeable results within two weeks of starting treatment. Many patients report reduced eye discomfort, burning, and irritation.

However, like all medications, Xiidra comes with potential side effects. The most commonly reported side effects include:

Temporary burning or discomfort when first applied
Unusual taste sensation (dysgeusia)
Reduced visual acuity
Eye irritation
Headache

Most side effects are mild and tend to diminish with continued use. If side effects persist or worsen, patients should consult their healthcare provider. It's worth noting that in clinical trials, discontinuation rates due to adverse effects were relatively low, suggesting that most patients tolerate the medication well.

Cost and Insurance Coverage in Canada

For Canadian patients, the cost of Xiidra can be a significant consideration. Without insurance coverage, a month's supply typically costs between $450-$550 CAD. However, several options exist to help manage these costs.

Many private insurance plans in Canada provide coverage for Xiidra, though coverage levels vary by provider and specific plan. Patients should check with their insurance provider about coverage details, including whether prior authorization is required. Some plans may require patients to try other treatments before covering Xiidra.

Novartis Pharmaceuticals Canada, the distributor of Xiidra in Canada, offers a patient support program that may provide financial assistance to eligible patients. Additionally, the Canadian Agency for Drugs and Technologies in Health periodically reviews medications for potential inclusion in provincial formularies, which could affect public coverage options in the future.

Patients without insurance coverage might consider discussing with their healthcare provider about potential alternatives or exploring compassionate access programs that might be available through the manufacturer.

Conclusion

Xiidra represents an important treatment option for Canadians suffering from chronic dry eye disease. By targeting the inflammatory processes underlying the condition, it offers potential relief beyond what temporary lubricating drops can provide. While considerations around cost and insurance coverage remain important factors in treatment decisions, the medication's proven efficacy makes it worth discussing with your eye care professional if you're struggling with persistent dry eye symptoms.

Before starting any new medication, including Xiidra, it's essential to have a comprehensive eye examination to confirm the diagnosis of dry eye disease and rule out other potential causes of eye discomfort. Your eye care provider can help determine if Xiidra is right for your specific situation and guide you through the process of obtaining and using this medication effectively.

Citations

This content was written by AI and reviewed by a human for quality and compliance.